Penn study finds relationship between PTEN loss, potential for immune response in BRCA 1/2-deficient ovarian cancer

(University of Pennsylvania School of Medicine) he protein known as phosphatase and tensin homolog (PTEN) is frequently mutated or affected by cancer as tumors develop. Now a new study from the Basser Center for BRCA at the Abramson Cancer Center of the University of Pennsylvania shows PTEN may serve as a marker for whether a patient with BRCA 1-2 deficient ovarian cancer is likely to respond to checkpoint inhibitor therapy.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news